• No results found

Nyrstar - additional information following the Shareholders’ Meeting (1.7.2019) | Vlaamse Federatie van Beleggers

N/A
N/A
Protected

Academic year: 2022

Share "Nyrstar - additional information following the Shareholders’ Meeting (1.7.2019) | Vlaamse Federatie van Beleggers"

Copied!
1
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Hele tekst

(1)

BRU11525890/5 167729-0002

Regulated Information

Nyrstar discloses additional information following the Shareholders’ Meeting of 25 June 2019

1 July 2019 at 07:00 CEST

Nyrstar NV ("Nyrstar" or the “Company” and, together with its subsidiaries, the “Group”) today announces that it has published on the Company website the following documents:

- a series of “Frequently Asked Questions” with answers relating to the capital structure review and restructuring process;

- the verbal questions and answers from the Shareholders’ Meeting of 25 June 2019; and

- documents that were placed at the disposal of the bondholders in respect of the implementation of the Lock-up Agreement (particularly but not only at the occasion of the vote on 21 May 2019).

The Company advises that a set of documents containing confidential (but not inside) information is now also available to current shareholders and bondholders of Nyrstar (the “Confidential Documents”) via an Online Data Room. Access to the Online Data Room can be obtained by current shareholders and bondholders of Nyrstar NV by emailing Confidential.info@nyrstar.com with the applicant’s full name, email address and proof of current shareholding or bondholding in Nyrstar. On receipt of satisfactory proof of a current holding, Nyrstar will email the applicant a username, password and link to access the Confidential Documents. It should be noted that the Confidential Documents cannot be saved or printed. The Confidential Documents include the following:

- the lock-up agreement dated 14 April 2019 between Nyrstar and/or its subsidiaries and certain of its financial creditors (the “Lock-up Agreement”);

- documents executed by Nyrstar and/or its subsidiaries that relate to the implementation of the restructuring provided for in the Lock-up Agreement, including the list of assets and liabilities that are transferred to NN2 NewCo Ltd;

- agreements between Nyrstar and/or its subsidiaries and Trafigura and/or its subsidiaries, that have a material impact on the financial flows between both groups; and

- a report from KPMG AG as independent expert advisor to the Board of Directors in respect of certain of the agreements with Trafigura.

About Nyrstar

Nyrstar is a global multi-metals business, with a market leading position in zinc and lead, and growing positions in other base and precious metals, which are essential resources that are fuelling the rapid urbanisation and industrialisation of our changing world. Nyrstar has mining, smelting and other operations located in Europe, the Americas and Australia and employs approximately 4,100 people. Nyrstar is incorporated in Belgium and has its corporate office in Switzerland. Nyrstar is listed on Euronext Brussels under the symbol NYR. For further information please visit the Nyrstar website: www.nyrstar.com.

For further information

Anthony Simms Head of Investor Relations T: +41 44 745 8157 M: +41 79 722 2152 E: anthony.simms@nyrstar.com Franziska Morroni Head of Communications T: +41 44 745 8295 M: +41 79 719 2342 E: franziska.morroni@nyrstar.com

Referenties

GERELATEERDE DOCUMENTEN

(a) Registration: Firstly, the right for a holder of securities to participate to and, as applicable, to vote at the extraordinary general shareholders' meeting is only

Solvac announces that all the documents relative to the Ordinary and Extraordinary General Shareholders' Meetings of May 14, 2019 are available in French or Dutch on www.solvac.be

The Consent Solicitations relate to changes to be made to the High Yield Notes primarily in respect of the accession of a co-obligor, amendments to the governing law and

Brussels, Belgium, 29 May 2019, 7.00 am (CET) – ASIT biotech (Euronext: ASIT - BE0974289218), a Belgian clinical-stage biopharmaceutical company focused on the research,

Nyrstar is a global multi-metals business, with a market leading position in zinc and lead, and growing positions in other base and precious metals, which are

Dijkhuizen - who was unable to participate in the meeting due to the current COVID-19 travel advice from the Belgian government for the Netherlands – would have expired following

MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company directors' or managements'